How new drugs are discovered in the 21st century
Drug discovery and development is a multi-step, interdisciplinary process that easily can take over a decade. People outside of the drug discovery and development process often ask why? Why does it take so long to move a new therapeutic idea into the clinic to benefit patients? Why can’t it happen sooner?
Come along to a panel discussion, led by the Griffith Insitute for Drug Discovery. Join with chemists, biologists and developers working on solving some of the most troubling and widespread diseases on the globe, to discuss the many factors that influence how fast a drug candidate progresses through development towards the clinic and into
WHERE: QCA Lecture Theatre and Gallery Building – S05, South Bank Campus
WHEN: Tuesday 21 May 2019
TIME: 5:30 pm – 7:00 pm with networking opportunity after the event
MODERATOR – Professor Katherine Andrews
Professor Kathy Andrews is the acting Director, Griffith Institute for Drug Discovery, and Head, Tropical Parasitology Laboratory. Her work focuses on the discovery of new drugs for malaria prevention and treatment.
Associate Professor Rohan Davis
Associate Professor Rohan Davis is a natural products chemist with the Griffith Institute for Drug Discovery. Rohan’s research is primarily focused on the identification of new anti-cancer and anti-infective agents from nature.
Ms Moana Simpson – Moana Simpson, the Manager of Compounds Australia, has over 20 years’ experience in providing support for drug discovery research within Australia and the UK, both in academia and in the pharmaceutical industry.
Professor Vicky Avery –
Professor Vicky Avery is Head, Discovery Biology, Griffith Institute for Drug Discovery and Head, Griffith University Drug Discovery Programme, CRC for Cancer Therapeutics. Her laboratory undertakes both basic and applied research in drug discovery, primarily in the areas of cancer and neglected diseases (Malaria, Chagas, African sleeping sickness and Leishmania).
Professor Jonathan Baell Larkins Fellow, Professor Jonathan Baell is Professor of Medicinal Chemistry at
Monash Institute of Pharmaceutical Sciences, Larkins Fellow, and Co-Director of the Australian Translational Medicinal Chemistry Facility. His research interests include high throughput screening library design, hit-to-lead medicinal chemistry, infectious and neglected diseases, epigenetic modifiers and anticancer medicinal chemistry, and peptidomimetic design and synthesis.
Emeritus Professor Maree Smith –
Maree Smith is Emeritus Professor and Director of the Centre for Integrated Preclinical Drug Development at The University of Queensland. Internationally, Professor Smith is a leading researcher in biomedical discovery/translation with particular expertise in the novel pain therapeutics field.